Efficacy and safety of Pien Tze Huang capsules in patients with herpes zoster: A multicenter, randomized, double-blinded, and placebo-controlled trial.

BACKGROUND: Herpes zoster (HZ) is a common medical condition accompanied by several distressing symptoms, including acute pain. Pien Tze Huang (PZH) is a well-known traditional Chinese medicine (TCM) with numerous pharmacological effects, including antiviral properties, neuroprotection, and immunity regulation. PURPOSE: To investigate the efficacy and safety of PZH capsules in patients with HZ. STUDY DESIGN: A multicenter, double-blinded, randomized, and placebo-controlled trial from 8 hospitals in 5 cities of China. METHODS: Eligible participants were randomly assigned to the PZH capsule and placebo group at a 1:1 ratio. Treatment was conducted for 14 days with a window period of no more than 2 days. For the first 7 days, participants received antiviral drugs combined with PZH capsules (0.6 g/time, 3 times a day) or placebos. For the remaining 7 days, they were only treated with PZH capsules (0.6 g/time, 3 times a day) or placebos. RESULTS: We included 222 patients in the full analysis set (FAS), and 187 patients in the per protocol set (PPS). The change of numeric rating scale pain scores from baseline to the seventh day (±1 day) after treatment in the PZH capsule group was statistically superior to the placebo group (FAS: 2.33 vs. 1.71, 97.5%CI: 0.03 ∼ 1.19; PPS: 2.29 vs. 1.51, 97.5%CI: 0.18 ∼ 1.38). In the PPS, there was a significant difference in the time (days) of pain relief between the placebo group and the PZH capsule group (Mean (SD): 5.71 (3.76) vs. 4.69 (3.57), p = 0.046). On the seventh day (±1 day) after treatment, the level of CD8+ cells in the PZH capsule group were higher than those of the placebo group (FAS: Mean (SD): 24.08 (6.81) vs. 21.93 (8.19), p = 0.007; PPS: Mean (SD): 24.26 (6.93) vs. 22.15 (8.51), p = 0.012). The level of cytotoxic lymphocyte cells found similar results on the seventh day (±1 day) (FAS: Mean (SD): 12.17 (4.65) vs. 10.55 (4.15), p = 0.018; PPS: Mean (SD): 12.25 (4.65) vs. 10.11 (3.93), p = 0.002). No serious adverse events were noted and PZH capsules were well tolerated. CONCLUSION: PZH capsules confer therapeutic effects on HZ with the TCM symptom of stagnated heat of liver channel by substantially reducing the pain intensity, shortening the time of pain relief as well as regulating the immune function. On the basis of the efficacy and safety profiles, PZH capsules may be a promising complementary therapy for the treatment of HZ.

Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort).

INTRODUCTION: This planned multicenter observational study will evaluate the overall survival of those undergoing integrated Chinese and Western medicine for stage IIIb-IVb non-small cell lung cancer and analyze the factors related to the prognosis. METHOD AND ANALYSIS: The prospective cohort will enroll patients with stage IIIb-IVb NSCLC from March 1, 2019, to December 31, 2025, and follow them for 5 years. We plan to collect data on the patients' demographics, treatment, overall survival, and factors related to the prognosis. ETHICS AND DISSEMINATION: The institutional review board and ethics committee reviewed the study protocol. All patients will provide informed consent before enrollment.Trial registration number: ChiCTR1900021430.

Anticolon Cancer Targets and Molecular Mechanisms of Tao-He-Cheng-Qi Formula.

Background: Tao-He-Cheng-Qi Formula (THCQF) is a traditional Chinese medicine that has been proven to have antitumor effects. The aim of this study was to elucidate the molecular targets and mechanisms of THCQF against colon cancer and construct a prognostic model based on network pharmacology, bioinformatics analysis, and in vitro experiments. Methods: Potential THCQF compounds and targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine databases. Differentially expressed genes for colon cancer were screened in The Cancer Genome Atlas and Gene Expression Omnibus databases. The anticolon cancer mechanisms of THCQF were explored using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking simulations and molecular dynamics analysis were used to evaluate the binding between target proteins and active compounds. Finally, the identified compounds were used to treat colon cancer cells from the HCT116 cell line, and expression of mRNA and protein after relevant posttreatment were tested using real-time polymerase chain reaction and western blotting. Results: A total of 27 anticolon cancer targets of THCQF were selected, among which four genes (CCNB1, CCNA2, IL1A, and MMP3) were shown to effectively predict patient outcomes in a prognostic colon cancer model. GO and KEGG enrichment analyses indicated that the activity against colon cancer of THCQF was associated with the interleukin (IL)-4 and IL-3 signaling pathways. Two compounds in THCQF, aloe emodin (AE) and quercetin (QR), were shown to efficiently bind to cyclin B1, the protein encoded by CCNB1. Finally, incubation of HCT116 cells with AE and QR significantly decreased CCNB1 mRNA expression and cyclin B1 levels. Conclusions: Taken together, the results indicate that AE and QR are the pivotal active compounds of THCQF, and CCNB1 is the main molecular target through which THCQF exerts its anticolon cancer effects. The study findings provide insight for studies investigating the anticancer effects of other traditional Chinese medicines.

Database mining and animal experiment-based validation of the efficacy and mechanism of Radix Astragali (Huangqi) and Rhizoma Atractylodis Macrocephalae (Baizhu) as core drugs of Traditional Chinese medicine in cancer-related fatigue.

ETHNOPHARMACOLOGICAL RELEVANCE: In China, Traditional Chinese medicine (TCM) is often used as the main therapy for cancer-related fatigue (CRF). However, there is limited evidence to prove its therapeutic effect and mechanism. AIM OF THE STUDY: We aimed to provide a basis for the therapeutic effect of TCM for CRF. MATERIALS AND METHODS: We performed a meta-analysis to investigate the efficacy of TCM treatment for CRF. Through frequency statistics and association rule mining, we screened the core Chinese medicine components, Astragalus mongholicus Bunge., root (Radix astragali, Huangqi) and Atractylodes macrocephala Koidz., rhizome (Rhizoma atractylodis macrocephalae, Baizhu). We then used animal experiments to verify the effectiveness of these two TCMs and changes in related indicators in mice. Relevant molecular mechanisms were explored through network pharmacological analysis. RESULTS: Twenty-four randomised control trials (RCTs) involving 1865 patients were included in the meta-analysis. TCM produced more positive effects on CRF than standard therapy alone. Radix astragali and Rhizoma atractylodis macrocephalae, as the core drug pair for the treatment of CRF, enhanced the physical fitness of mice; reduced abdominal circumference, level of inflammatory factors, and tumour weight; and increased body weight and blood sugar. Network pharmacology analysis showed that the mechanism of action of Radix astragali and Rhizoma atractylodis macrocephalae on CRF mainly involved compounds, such as quercetin, kaempferol and luteolin, acting through multiple targets, such as Protein kinase B α (AKT1), Tumour necrosis factor (TNF), and Interleukin-6 (IL-6). These molecules regulate cytokines, cancer signalling, and metabolic pathways and confer an anti-CRF effect. CONCLUSIONS: TCM may be a promising therapy to relieve CRF in cancer patients. Our research may provide a reference for the clinical application of TCM for treating CRF.

Kinetic and equilibrium of U(VI) biosorption onto the resistant bacterium Bacillus amyloliquefaciens.

This study evaluated U(VI) biosorption properties by the resistant bacterium, Bacillus amyloliquefaciens, which was isolated from the soils with residual radionuclides. The effect of biosorption factors (uptake time, pH, ionic concentration, biosorbent dosage and temperature) on U(VI) removal was determined by batch experiments. The uptake processes were characterized by using SEM, FTIR, and XPS. The experimental data of U(VI) biosorption were fitted by the pseudo-second-order. The maximum uptake capacity was 179.5 mg/g at pH 6.0 by Langmuir model. The thermodynamic results: ΔGо, ΔHо and ΔSо for uptake processes were calculated as -6.359 kJ/mol, 14.20 kJ/mol and 67.19 J/mol/K, respectively. The results showed that the biosorption of Bacillus amyloliquefaciens will be an ideal method to remove radionuclides.

Effect of Staphylococcus epidermidis on U(VI) sequestration by Al-goethite.

Effect of Staphylococcus epidermidis (S. epidermidis) on U(VI) sequestration by Al-goethite were conducted under different geologic conditions. The batch experiments showed that S. epidermidis significantly enhanced the adsorption rates of U(VI) at pH < 9.0 due to the additional metal binding sites. The maximum adsorption capacities of U(VI) on Al-goethite and Al-goethite +S. epidermidis at pH 4.0 and 310 K were calculated from Langmuir equation to be 13.16 and 47.86 mg/g, respectively. The decreased adsorption of U(VI) on Al-goethite+ S. epidermidis at high carbonate and pH conditions were primarily driven by the electrostatic repulsion between negatively charged U(VI)-carbonate complexes and the negatively charged adsorbents. According to XPS analysis, the adsorbed U(VI) can be reduced to U(IV) by S. epidermidis, whereas inhibited reduction of U(VI) on Al-goethite + S. epidermidis at high pH could be attributed to the complexation of structural Fe(III) with the oxygen-containing functional groups of S. epidermidis. FT-IR analysis further demonstrated that the bonding of structural Fe(III) with functional groups (e.g., carboxyl and phosphate groups) of S. epidermidis. These results herein are important to understand the fate and transport of U(VI) on the mineral-bacteria ternary systems in the near-surface environment.

Accumulation of U(VI) on the Pantoea sp. TW18 isolated from radionuclide-contaminated soils.

Pantoea sp. TW18 isolated from radionuclide-contaminated soils was used for the bioremediation of radionuclides pollution. Accumulation mechanism of U(VI) on Pantoea sp. TW18 was investigated by batch experiments and characterization techniques. The batch experiments revealed that Pantoea sp. TW18 rapidly reached accumulation equilibrium at approximately 4 h with a high accumulation capacity (79.87 mg g-1 at pH 4.1 and T = 310 K) for U(VI). The accumulation data of U(VI) onto Pantoea sp. TW18 can be satisfactorily fitted by pseudo-second-order model. The accumulation of U(VI) on Pantoea sp. TW18 was affected by pH levels, not independent of ionic strength. Analysis of the FT-IR and XPS spectra demonstrated that accumulated U(VI) ions were primarily bound to nitrogen- and oxygen-containing functional groups (i.e., carboxyl, amide and phosphoryl groups) on the Pantoea sp. TW18 surface. This study showed that Pantoea sp. TW18 can be considered as a promising sorbent for remediation of radionuclides in environmental cleanup.